Meeting
2020 ASCO Virtual Scientific Program
KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers.
Authors
Kedar Kirtane
Moffitt Cancer Center, Tampa, FL
Kedar Kirtane , Erminia Massarelli , Glenn J. Hanna , Christopher Austin Klebanoff , George Blumenschein Jr., Michael Russell Bishop , Sylvia Lee , Jiaxin Niu , Sabina Adhikary , Stephanie H. Astrow , Katherine Rodriguez , Rong Chu , A. Scott Jung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03912831
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3149)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3149
Abstract #
TPS3149
Poster Bd #
213
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
First Author: Jiayong Liu
Poster
2023 ASCO Annual Meeting
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2023 ASCO Annual Meeting
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.
First Author: Suzanne Phillips
Poster
2023 ASCO Annual Meeting
TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.
First Author: Qingzhu Jia